Power Doppler Perfusion Phenotype in RA May Be Dependent on ANCA Status
Power Doppler perfusion phenotype was dependent on anti-citrullinated peptide antibody status, but not on rheumatoid factor status.
Rheumatoid Arthritis
Assessing Economic Effects of Cycling vs Swapping After Initial TNFi Failure in RA
Investigators reviewed economic analyses comparing cycling TNFi with swapping with another therapy in patients with rheumatoid arthritis who did not respond to initial TNFi therapy.
Discrete Trajectories of Persistent Pain Identified in Rheumatoid Arthritis
In patients with rheumatoid arthritis treated with anti-inflammatory medications, long-term persistent pain was found to be common and may be predicted by higher levels of disability and a history of smoking.
Short-Term Structural Changes Associated With Functional Assessments in RA
Quantitative assessment appears to be more sensitive than semiquantitative grading for the detection of subtle, short-term changes in patients with RA.
Quitting Smoking Lowers Rheumatoid Arthritis Risk
Researchers examined whether smoking cessation may delay or prevent the onset of rheumatoid arthritis. Review their findings.
Peripheral Lymphocyte Multidrug Resistance Activity May Aid Biologic Therapeutic Response Prediction in RA
Researchers assessed the predictive value of multidrug resistance transporter activity for biologic therapeutic response in RA.
FDA Recommendations and Safety Concerns With Higher Dose of Tofacitinib in Post-Marketing Study
Tofacitinib dosed at 10mg twice daily was associated with an increased risk of pulmonary embolism and overall mortality in patients with rheumatoid arthritis.
Efficacy and Safety of Biosimilar CT-P10 vs Reference Rituximab in Rheumatoid Arthritis
Investigators examined the long-term clinical outcomes of extended treatment with biosimilar CT-P10 and 2 approved rituximab reference products in patients with rheumatoid arthritis.
ACF Antibody Diagnostic Accuracy Evaluated in Rheumatoid Arthritis
Data show that the ACF antibody can be used as the complementary biomarker in RA diagnosis.
Safety Concerns Raised With Higher Dose of Tofacitinib in Post-Marketing Study
Pfizer has announced its intention to transition patients with rheumatoid arthritis who were receiving tofacitinib 10 mg twice daily to receive tofacitinib 5 mg twice daily in its post-marketing study.
Next post in Rheumatoid Arthritis
